- Home
- TRTX vs CVAC Comparison
TRTX vs CVAC Comparison
Compare TRTX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRTX
- CVAC
- Stock Information
- Founded
- TRTX 2014
- CVAC 2000
- Country
- TRTX United States
- CVAC Germany
- Employees
- TRTX N/A
- CVAC N/A
- Industry
- TRTX Real Estate Investment Trusts
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- TRTX Real Estate
- CVAC Health Care
- Exchange
- TRTX Nasdaq
- CVAC Nasdaq
- Market Cap
- TRTX 648.4M
- CVAC 764.4M
- IPO Year
- TRTX 2017
- CVAC 2020
- Fundamental
- Price
- TRTX $7.92
- CVAC $5.44
- Analyst Decision
- TRTX Strong Buy
- CVAC Buy
- Analyst Count
- TRTX 4
- CVAC 3
- Target Price
- TRTX $9.50
- CVAC $9.00
- AVG Volume (30 Days)
- TRTX 553.6K
- CVAC 2.2M
- Earning Date
- TRTX 07-29-2025
- CVAC 08-14-2025
- Dividend Yield
- TRTX 12.14%
- CVAC N/A
- EPS Growth
- TRTX N/A
- CVAC N/A
- EPS
- TRTX 0.70
- CVAC 0.87
- Revenue
- TRTX $148,005,000.00
- CVAC $566,039,775.00
- Revenue This Year
- TRTX N/A
- CVAC N/A
- Revenue Next Year
- TRTX $9.19
- CVAC $24.04
- P/E Ratio
- TRTX $11.32
- CVAC $6.28
- Revenue Growth
- TRTX N/A
- CVAC 787.60
- 52 Week Low
- TRTX $6.47
- CVAC $2.37
- 52 Week High
- TRTX $9.66
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- TRTX 54.53
- CVAC 68.03
- Support Level
- TRTX $7.83
- CVAC $4.07
- Resistance Level
- TRTX $8.13
- CVAC $5.58
- Average True Range (ATR)
- TRTX 0.14
- CVAC 0.20
- MACD
- TRTX 0.00
- CVAC 0.07
- Stochastic Oscillator
- TRTX 66.92
- CVAC 83.08
About TRTX TPG RE Finance Trust Inc.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.